---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-26-007306"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2026-08-05T20:30:26+00:00"
generated_at: "2026-08-05T20:31:17.045576+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q2 revenue $9.5M (+37% YoY), net loss down 49% to $3.8M

## Summary
- Record Q2 revenue of $9.5M, up 37% YoY; net loss reduced 49% to $3.8M from $7.4M.
- Diagnostics segment revenue grew 77% to $1.4M; Therapeutic Devices up 9% to $6.8M.
- Cash burn improved 38% to $3.4M; operating expenses down 20% to $10.1M.
- Cash and securities $44.1M; 22nd consecutive quarter of YoY revenue growth.
- Development Services segment contributed $1.4M in Q2, $3.4M YTD.

## SEC filing metadata
- accession: 0001654954-26-007306
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2026-08-05T20:30:26+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/0001654954-26-007306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-26-007306
- JSON: https://secwatch.observer/filing/0001654954-26-007306.json
- Plain text: https://secwatch.observer/filing/0001654954-26-007306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.